Form 4: C4 Therapeutics Director Boosts Stake via Equity Compensation

C4 Therapeutics Director Donna Roy Grogan acquired 7,513 shares of common stock at $1.93 per share, increasing her direct beneficial ownership to 66,142 shares.

Summary

• Donna Roy Grogan, a Director of C4 Therapeutics, Inc. (CCCC), acquired 7,513 shares of the company's common stock.
• The transaction occurred on January 2, 2026, with shares priced at $1.93 each.
• The acquisition was made pursuant to the Issuer's Non-Employee Director Compensation Policy, where Ms. Grogan elected to receive shares in lieu of cash compensation for her services.
• Following this transaction, Ms. Grogan directly beneficially owns a total of 66,142 shares of C4 Therapeutics common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.

Sentiment

Score: 7

Explanation: The sentiment is positive. A director choosing to receive equity over cash compensation signals confidence in the company's long-term value and aligns their interests with shareholders. This is generally viewed favorably by investors.

Positives

• A Director elected to receive equity compensation (shares) instead of cash, indicating confidence in the company's future prospects.
• The acquisition increases the Director's direct beneficial ownership in the company to 66,142 shares, aligning her interests further with shareholders.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned and systematic approach to equity accumulation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, but the director's election to receive equity compensation can be interpreted as a positive signal of future confidence.

Management Comments

• The Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer, in accordance with the Issuer's Non-Employee Director Compensation Policy.

Industry Context

Insider transactions, particularly acquisitions by directors, are often viewed by the market as a signal of confidence in the company's future prospects. In the biotechnology or pharmaceutical industry, where C4 Therapeutics operates, such signals can be particularly relevant given the long development cycles and inherent risks.

Corporate Governance

Related Party Transactions

• The acquisition of common stock by Director Donna Roy Grogan from C4 Therapeutics, Inc. as compensation for services is a related party transaction.

Stakeholder Impact

• Shareholders may view this transaction positively as it demonstrates a director's confidence in the company's future, potentially boosting investor sentiment.
• The company benefits from retaining cash by issuing equity for director compensation, which can be reinvested in operations.

Key Dates

Recommendation

A director's decision to receive equity compensation instead of cash, thereby increasing their stake, is a strong signal of confidence in the company's future performance and valuation. This insider buying, even if compensation-driven, suggests management believes the stock is a good long-term investment, warranting a 'buy' recommendation for investors seeking to align with informed insider sentiment.

Keywords

C4 Therapeutics, CCCC, Insider Transaction, Form 4, Director Stock Acquisition, Equity Compensation, Rule 10b5-1